CCRB Logo

Trial History Detail on 2015-10-13

CUHK_CCT00419

2014-06-24

Prospective

CREC 2014.283-T

Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong

Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong

N/A

Not Applicable

Ms Janice Wong

3/F, Hong Kong Eye Hospital, 147K, Argyle Street, Mongkok, Kowloon, Hong Kong

39435825

janicewong@cuhk.edu.hk

The Chinese University of Hong Kong

Hong Kong

Dr. Jhanji, Vishal

3/F, Hong Kong Eye Hospital, 147K, Argyle Street, Mongkok, Kowloon, Hong Kong

39435807

vishaljhanji@cuhk.edu.hk

Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong

Hong Kong

Randomized, Contralateral Eye Study to Evaluate the Safety and Efficacy of anti-glaucoma treatment for prevention of regression after Myopic LASIK

Randomized, Contralateral Eye Study to Evaluate the Safety and Efficacy of anti-glaucoma treatment for prevention of regression after Myopic LASIK

青光眼藥物治療用於控制近視LASIK術後回退的功效及安全性隨機對照臨床試驗

Safety and Efficacy of anti-glaucoma treatment for prevention of regression after Myopic LASIK

Hong Kong

Yes

2014-06-13

Kowloon West Cluster Research Ethics Committee

2014.283-T

Refractive error

Drug

preservative free timolol 0.5% eye drops

0.5%

0.5%

started at 1 week after surgery and would be continued up to 3 months postoperatively

Twice daily

Not Applicable

Not Applicable

Not Applicable

Not Applicable

Not Applicable

1. Patients with myopia or myopic astigmatism aged 21 years or more
2. Anisometropia < 1 diopter

1. Patients aged < 21 years
2. Patients in which the target refraction is not emmetropia
3. Patients with ocular inflammation, diabetes mellitus, connective tissue disorders
4. Patients who have used retinoid acid or equivalent in the past 6 months
5. Patients with known cardiac disease or bronchial asthma

21 years old

999 years old

Both Male and Female

Interventional

Randomized

One randomly chosen eye of each patient would receive preservative free timolol 0.5% eye drops.

Placebo

Single-blind

Investigator/research team

Parallel

Other

NA

2014-07-09

87

Not Yet Recruiting

1. Spherical equivalent
2. Uncorrected visual acuity (UCVA)

1. Change in corneal curvature as observed on the corneal topography
2. Change in corneal thickness on corneal topography
3. Adverse effects associated with the treatment

No

2016-04-08

ChiCTR-TRC-14004839 

2014-06-24

Type Access Document Published On  
No documents yet.
  • Page 1 of 1.